ICH Study Center Gmbh & Co. KG

The trials here

What the 13 trials at this site are about, from their registry records.

Conditions

• HIV10 trials
• Hepatitis B2 trials
• Psoriasis1 trial

Phase

• Phase 36 trials
• Phase 23 trials
• Phase 2/33 trials
• Phase 41 trial

Status

• Active, not recruiting5 trials
• Completed5 trials
• Recruiting3 trials

Lead sponsor

• Gilead Sciences Inc.5 trials
• ViiV Healthcare3 trials
• GlaxoSmithKline2 trials
• Justus-Liebig-Universitaet Giessen1 trial
• Merck Sharp & Dohme LLC1 trial
• and 1 more

Running trials

• Recruiting

  Study of an Injectable Regimen of GS-3242 with Lenacapavir Compared to Biktarvy in People New to HIV-1 Treatment

  2026-526026-40-00· Phase 2/3· Gilead Sciences Inc.· Source

• Recruiting

  Study of Lenacapavir, Teropavimab, and Zinlirvimab in Virologically Suppressed Adults With HIV-1 on Stable Oral Treatment Regimens

  2025-524336-19-00· Phase 3· Gilead Sciences Inc.· Source

• Recruiting

  A Phase 2b Study Evaluating Oral VH4524184 Regimens in Treatment Naïve Persons With HIV-1 (INNOVATE Study)

  NCT07202546· Phase 2· ViiV Healthcare· Source

• Active, not recruiting

  Study to Compare an Oral Weekly Islatravir/Lenacapavir Regimen With Bictegravir/Emtricitabine/Tenofovir Alafenamide in Virologically Suppressed People With HIV-1 (ISLEND-1)

  NCT06630286· Phase 3· Gilead Sciences Inc.· Source

• Active, not recruiting

  A clinical study of people with HIV-1 who have not taken antiretroviral therapy, one group will start treatment with a combination of doravirine and Islatravir compared to a different group that will start treatment with bictegravir/emtricitabine/tenofovir alafenamide

  NCT05705349· Phase 3· Merck Sharp & Dohme LLC· Source

• Active, not recruiting

  A Study to Evaluate the Efficacy, Safety, and Tolerability of Using an Oral Once-daily 2 Drug Regimen Compared to an Oral Once-daily 3 Drug Regimen for the Treatment of Human Immunodeficiency Virus (HIV)-1 in Adults Who Have Not Previously Taken Antiretroviral Therapy

  NCT05979311· Phase 3· ViiV Healthcare· Source

• Recruiting

  Safety and immunologic response of SHIngrix VAccination in patients suffering from Psoriasis or Psoriatic arthritis

  2024-512881-32-00· Phase 4· Justus-Liebig-Universitaet Giessen· Source

• Active, not recruiting

  Long-term Follow-up Study to Evaluate Durability of Treatment Response in Previous Bepirovirsen Study Participants (B-Sure)

  NCT04954859· Phase 2· GlaxoSmithKline· Source

Recruiting at the same time

How many trials recruit for the same indication here at once. A count, not a rating.

• HIV2 recruiting
• Psoriasis1 recruiting

Closed trials

• Completed

  Study of Oral Weekly GS-1720 and GS-4182 Compared With Biktarvy in People With HIV-1 Who Have Not Been Treated

  2024-512505-66-00· Phase 2/3· Gilead Sciences Inc.· Source

• Completed

  Study of Oral Weekly GS-1720 and GS-4182 Versus Biktarvy in People With HIV-1 Who Are Virologically Suppressed

  NCT06544733· Phase 2/3· Gilead Sciences Inc.· Source

• Completed

  Proof of Concept Treatment Study of Orally Administered VH4004280 or VH4011499 in HIV-1 Infected Adults

  NCT06039579· Phase 2· ViiV Healthcare· Source

• Completed

  Study of Bepirovirsen in Nucleos(t)Ide Analogue-treated Participants With Chronic Hepatitis B (B-Well 2)

  NCT05630820· Phase 3· GlaxoSmithKline· Source

• Completed

  The Late Presenter Treatment Optimisation Study

  NCT03696160· Phase 3· NEAT ID Foundation· Source